Task force 1. Pathogenesis of coronary disease: The biologic role of risk factors

Journal of the American College of Cardiology

Volumn 27, Issue 5, 1996, Pages 964-976

  Fuster, Valentin ^b   Gotto Jr , Antonio M ^b   Libby, Peter ^b   Loscalzo, Joseph ^b   McGill Jr , Henry C ^b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN;

ATHEROSCLEROSIS; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET; HEREDITY; HUMAN; HYPERTENSION; OBESITY; PRIORITY JOURNAL; RISK FACTOR; SMOKING; THROMBOSIS; FEMALE; MALE; PATHOPHYSIOLOGY; REVIEW;

CORONARY DISEASE; FEMALE; HUMANS; MALE; RISK FACTORS;

EID: 0030117367     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(96)00014-9     Document Type: Conference Paper

References (82)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362(6423):801-9.
2. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994;90(4):2126-46.
3. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87(6):1781-91.
4. Blankenhorn DH, Hodis HN. George Lyman Duff Memorial Lecture. Arterial imaging and atherosclerosis reversal. Arterioscler Thromb 1994; 14(2):177-92.
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383-9.
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333: 1301-7.
7. Maseri A, Crea KF, Cianflone D. Myocardial ischemia caused by distal coronary vasoconstriction. Am J Cardiol 1992;70:1602-5.
8. Reddy KG, Nair RN, Sheehan HM, Hodgson JM. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol 1994;23(4):833-43.
9. Egashira K, Inou T, Hirooka Y, Yamade A, Urabe Y, Yakeshita A. Evidence of impaired endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary angiograms. N Engl J Med 1993;23: 1659-64.
10. Stary HC. Composition and classification of human atherosclerotic lesions. Virchows Arch A Pathol Anat Histopathol 1992;421(4):277-90.
11. Stary HC. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. Circulation 1994;89(5):2462-78.
12. Steinberg D. Antioxidants and atherosclerosis. A current assessment. Circulation 1991;84(3):1420-5.
13. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326(5):310-8.
14. Nissen SE, Gurley JC, Grines CL, et al. Intravascular ultrasound assessment of lumen size and wall morphology in normal subjects and patients with coronary artery disease. Circulation 1991;84(3): 1087-99.
15. Hangartner JR, Charleston AJ, Davies MJ, Thomas AC. Morphological characteristics of clinically significant coronary artery stenosis in stable angina. Br Heart J 1986;56(6):501-8.
16. Ambrose J, Tannenbaum M, Alexpoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988;12:56-62.
17. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease. Circulation 1988;78(5 Pt 1):1157-66.
18. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983;50(2): 127-34.
19. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993;69(5):377-81.
20. Sherman CT, Litvack F, Grundfest W, et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986;315(15):913-9.
21. Richardson PD, Davies MJ, Born GV. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989;2(8669):1462-3.
22. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994;90(2):775-8.
23. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94(6):2493-503.
24. Galis ZS, Sukhova GK, Kranzhofer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 1995;92(2):402-6.
25. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303(16):897-902.
26. Maseri A, L'Abbate A, Baroldi G, et al. Coronary vasospasm as a possible cause of myocardial infarction. A conclusion derived from the study of preinfarction angina. N Engl J Med 1978;299(23):1271-7.
27. Bogaty P, Hackett D, Davies G, Maseri A. Vasoreactivity of the culprit lesion in unstable angina. Circulation 1994;90(1):5-11.
28. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263(5579):663-5.
29. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288(5789):373-6.
30. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332(6163):411-5.
31. Egashira K, Inou T, Hirooka Y, et al. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest 1993;91(1):29-37.
32. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation 1989;80(1):198-205,
33. Braunwald E, Jones RH, Mark DB, et al. Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. Circulation 1994; 90(1):613-22.
34. Chesebro JH, Webster MW, Zoldhelyi P, Roche PC, Badimon L, Badimon JJ, Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins. Circulation 1992;86(Suppl III):III-100-10.
35. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985;71(4):699-708.
36. Goldstein JL, Brown MS. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem 1977:46:897-930.
37. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Summary of the Second Report of the National Cholesterol Education Program (NCEP). JAMA 1993;269(23):3015-23.
38. Schulte JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature 1993;365(6448):762-4.
39. Hodis HN, Mack WJ, Azen SP, et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994;90(1):42-9.
40. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation 1990;81(2):470-6.
41. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992;70(7):733-7.
42. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992;85(1):37-45.
43. Simon DI, Ezratty AM, Loscalzo J. Lipoprotein(a) and atherothrombosis. Curr Opin Lipidol 1993;8:814-20.
44. Committee on Diet and Health Food and Nutrition Board Co. Chapter 7. Diet and Health. Washington, D.C.: National Academy Press; 1989:7.
45. Panza JA, Quyyumi AA, Brush JE, Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990;323(1):22-7.
46. Schwartz SM, Campbell GR, Campbell JH. Replication of smooth muscle cells in vascular disease. Circ Res 1986;58(4):427-44.
47. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989;83(4):1419-24.
48. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83(5):1774-7.
49. Chobanian AV, Lichtenstein AH, Nilakhe V, Haudenschild CC, Drago R, Nickerson C. Influence of hypertension on aortic atherosclerosis in the Watanabe rabbit. Hypertension 1989;14(2):203-9.
50. Thijs L, Fagard R. Lijnen P, Staessen J, Van Hoff R, Amery A. J Hypertens 1992;10:1103-8.
51. Blythe WB, Maddux FW. Hypertension as a causative diagnosis of patients entering end-stage renal disease programs in the United States from 1980-1986. Am J Kidney Dis 1991;18:33-7.
52. Tejada C, Strong JP, Montenegro MR, Restrepo C, Solberg LA. Distribution of coronary and aortic atherosclerosis by geographic location, race, and sex. Lab Invest 1968;18(5):509-26.
53. Srinivasan SR, Wattigney W, Webber LS, Berenson GS. Race and gender differences in serum lipoproteins of children, adolescents, and young adults - emergence of an adverse lipoprotein pattern in white males: the Bogalusa Heart Study. Prev Med 1991;29(6):671-84.
54. A Report of the Surgeon General. U.S. Department of Health. Smoking and Health. U.S. Department of Health, Education and Welfare; 1979.
55. Hypertension prevalence and the status of awareness, treatment, and control in the United States. Final report of the Subcommittee on Definition and Prevalence of the 1984 Joint National Committee. Hypertension 1985;7(3 Pt 1):457-68.
56. Barrett-Connor E, Bush TL Estrogen and coronary heart disease in women. JAMA 1991;265(14):1861-7.
57. The Coronary Drug Project. Initial findings leading to modifications of its research protocol. JAMA 1970;214(7):1303-13.
58. McGinnis JM, Shopland D, Brown C. Tobacco and health: trends in smoking and smokeless tobacco consumption in the United States. Annu Rev Public Health 1987;8:441-67.
59. Enos WF Jr, Beyer JC, Holmes RH. Pathogenesis of coronary disease in American soldiers killed in Korea. JAMA 1955;158:912-4.
60. McGill HC Jr, McMahan CA, Malcom GT, Oalmann MC, Strong JP. Relation of glycohemoglobin and adioposity to atherosclerosis in youth. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vase Biol 1995;15(4):431-40.
61. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking: a preliminary report. JAMA 1990;264:3018-24.
62. Dotevall A, Johansson S, Wilhelmsen L. Association between fibrinogen and other risk factors for cardiovascular disease in men and women. Results from the Goteborg MONICA survey 1985. Ann Epidemiol 1994;4(5):369-74.
63. Celermajer DS, Sorensen KE, Gerogakopoulos D, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993; 88(5 Pt 1):2149-55.
64. Frei B, Forte TM, Ames BN, Cross CE. Gas phase oxidants of cigarette smoke induce lipid peroxidation and changes in lipoprotein properties in human blood plasma. Protective effects of ascorbic acid. Biochem J 1991; 277(Pt 1):133-8.
65. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Cayatte AJ, Rozek MM. Pathogenesis of the atherosclerotic lesion. Implications for diabetes mellitus. Circulation 1992;15(9):1156-67.
66. Genest JJ, Martin-Munley S, McNamara JR. Prevalence of familial lipopro-tein and secondary prevention of coronary artery disease. Ann Intern Med 1994;120:1012-25.
67. Rader DJ, Hoeg JM, Brewer HB Jr. Quantisation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 1994;120(12):1012-25.
68. Gaw A, Boerwinkle E, Cohen JC, Hobbs HH. Comparative analysis of the apo(a) gene, apo(a) glycoprotein, and plasma concentrations of Lp(a) in three ethnic groups. Evidence for no common null allele at the apo(a) locus, J Clin Invest 1994;93(6):2526-34.
69. Boers GH, Smals AG, Trijbels FJ, et al. Heterozygosity for homocysteinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313(12):709-15.
70. Genest JJ Jr, McNamara JR, Upson B, et al. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscler Thromb 1991;11(5):1129-36.
71. Meade TW, Mellows S, Brozovic M, et al. Hemostatic function and ischemic heart disease: Principle results of the Northwick Park Heart Study. Lancet 1986;2:533-7.
72. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction, N Engl J Med 1984;311(8):505.
73. Yan XC, Jing TY, Resnick LM, Phillips GB. Relation of hemostatic risk factors to other risk factors for coronary heart disease and to sex hormones in men. Arterioscler Thromb 1993;13(4):467-71.
74. Trip MD, Cats VM, van Capelle FJ, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990;322(22): 1549-54.
75. Thaulow E, Erikssen J. Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991;84(2);613-7.
76. Lam JY, Latour JG, Lesperance J, Waters D. Platelet aggregation, coronary artery disease progression and future coronary events. Am J Cardiol 1994;73(5):333-8.
77. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90(1):61-8.
78. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341(8854):1165-8.
79. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993;342(8879): 1076-9.
80. Barrett-Connor EL. Obesity, atherosclerosis, and coronary artery disease. Ann Intern Med 1985;103(6 Pt 2):1010-9.
81. Blair SN, Kohl HW, Barlow CE, et al. Changes in physical fitness and all-cause mortality. A prospective study of healthy and unhealthy men. JAMA 1995;273:1093-8.
82. Ekelund LG, Haskell WL, Johnson JL, Whaley FS, Criqui MH, Sheps DS. Physical fitness as a predictor of cardiovascular mortality in asymptomatic North American men. The Lipid Research Clinics Mortality Follow-up Study. N Engl J Med 1988;319(21):1379-84.